The CFAR Molecular Virology/Virology Core serves as a foundational support and important resource for AIDS investigators at AECOM and collaborating institutions. The technologic repertoire of the Core includes both quality-controlled routine and specialized HIV-1 methodologies, including (1) Molecular cloning and prorogation of HIV-1 isolates (2) Determination of acid-labile and acid-stable HIV-1 p24 antigen concentration; (3) HIV culture [Qualitative, Quantitative, Plasma, Tropism-Variant]; (4) HIV isolation and concentration; and (5) HIV neutralization. The Core has demonstrated ability and capacity for efficiently handling a large and diverse research and clinical specimen load, as reflected in its virologic support of numerous AECOM investigators as well as multiple ACTG sites. In addition, Core personnel encompass a brad range of expertise and experience in the field of retrovirology, with recognized contributions in HIV-1 research, forming an effective framework for stimulation of interactive multidisciplinary collaborations. These assets have enabled the Core to actively support research directed toward HIV-1 vaccine development, investigation of maternal-feta transmission of HIV, efficacy of therapeutic interventions in HIV disease, development of novel modalities for prevention of HIV-1 transmission via blood-products, research on the role of viral variants in maternal-fetal HIV transmission, evaluation of viral load in HIV- infected patients in clinical trials, and variety of additional basic and clinical AIDS-related research projects and clinical applications. The CFAR Virology Core provides access to state-of-the-art technologic support and to Core personnel having current scientifically sound expertise and experience in HIV-1 retrovirology, and thus furnishes an environment which promotes interactive, collaborative research and facilitates timely application of basic research to the clinical arena.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
United States
Zip Code
Rubinstein, Arye (2005) Preclinical studies of alkylureas as anti-HIV-1 contraceptive. Curr Pharm Des 11:3769-78
Lenz, J; Su, M; Mizrachi, Y et al. (2001) V3 variation in HIV-seropositive patients receiving a V3- targeted vaccine. AIDS 15:577-81
Browning Paul, J; Wang, E J; Pettoello-Mantovani, M et al. (2000) Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retroviruses 16:481-92
Rubinstein, A; Mizrachi, Y; Bernstein, L et al. (2000) Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS 14:F55-62
Yurasov, S V; Pettoello-Mantovani, M; Raker, C A et al. (1999) HIV type 1 infection of human fetal bone marrow cells induces apoptotic changes in hematopoietic precursor cells and suppresses their in vitro differentiation and capacity to engraft SCID mice. AIDS Res Hum Retroviruses 15:1639-52
Rubinstein, A; Mizrachi, Y; Pettoello-Mantovani, M et al. (1999) Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J Acquir Immune Defic Syndr 22:467-76
Pettoello-Mantovani, M; Kollmann, T R; Katopodis, N F et al. (1998) thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. J Infect Dis 177:337-46
Landor, M; Rubinstein, A; Kim, A et al. (1998) Receptor-mediated maternofetal transfer of immunoglobulins. Inhibition of transport of anti-HIV-1 immunoglobulin by generic immunoglobulins in the in vitro perfused placenta. Int Arch Allergy Immunol 115:203-9
Browning, J; Horner, J W; Pettoello-Mantovani, M et al. (1997) Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A 94:14637-41
Harish, Z; Rubinstein, A; Golodner, M et al. (1997) Suppression of HIV-1 replication by propolis and its immunoregulatory effect. Drugs Exp Clin Res 23:89-96

Showing the most recent 10 out of 36 publications